Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
2 NC counties are under alert, including Johnston County.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Crinetics Pharmaceuticals Inc
(NQ:
CRNX
)
53.15
-0.09 (-0.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
573,951
Open
53.94
Bid (Size)
53.13 (1)
Ask (Size)
53.15 (1)
Prev. Close
53.24
Today's Range
52.83 - 54.06
52wk Range
15.76 - 55.78
Shares Outstanding
54,026,103
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 12, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
A Closer Look at 11 Analyst Recommendations For Crinetics Pharmaceuticals
August 09, 2024
Via
Benzinga
Performance
YTD
+50.18%
+50.18%
1 Month
-0.36%
-0.36%
3 Month
+13.42%
+13.42%
6 Month
+37.45%
+37.45%
1 Year
+211.18%
+211.18%
More News
Read More
CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
August 08, 2024
Via
InvestorPlace
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals
June 28, 2024
Via
Benzinga
17 Analysts Have This To Say About Crinetics Pharmaceuticals
June 04, 2024
Via
Benzinga
18 Analysts Have This To Say About Crinetics Pharmaceuticals
May 14, 2024
Via
Benzinga
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
August 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
July 18, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
July 14, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
July 01, 2024
Via
Benzinga
7 Biotech Stocks to Boost Your Portfolio to Peak Health
June 26, 2024
Via
InvestorPlace
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
June 18, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
June 04, 2024
Via
Benzinga
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
June 03, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
June 03, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
May 30, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
May 22, 2024
Via
Benzinga
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
May 22, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
May 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
May 02, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.